WDLangbein

/Bill Langbein

About Bill Langbein

Before starting SanaCurrents, William (Bill) Langbein spent more than 20 years as a life science business journalist, with stops at California Medicine, In Vivo and Reuters Health. During that time, he wrote on genomic discoveries, the transition of the pharmaceutical companies to rely more on biologics, and the dawn of precision medicine, through which most drug developers came to recognize a one-drug-for-all approach would no longer work. One constant truth he learned is smaller companies deliver the most innovation and highest value to patients and investors. Yet because of the inherent volatility of biopharma and medical devices, small companies typically fly under the radar of investors. The emergence of precision medicine, however, reduces the volatility of small cap companies and increases the potential for strong returns. SanaCurrents was founded to identify the undervalued therapies that would benefit patients and investors the most.

Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts

One of the strongest performing biopharmaceutical stocks this year is [...]

ADMA New Catalysts For 2019 – Two PDUFA decisions on immunodeficiency therapies

SUMMARY SanaCurrents assigns a pivotal sentiment the FDA will approve [...]

Verona (VRNA) Talks Up The Long View Following Phase II Setback

Verona Pharma (NASDAQ:VRNA) highlighted a surprising benefit from a lower [...]

Cara Therapeutics (CARA) Q1 2019 Catalyst: Phase III efficacy trial, KALM-2

SUMMARY Sana Currents assigns a pivotal sentiment that Cara Therapeutics [...]

ADMA Biologics Believes It Can Resolve CRL Issues Quickly, Spring Review Possible

Shares of ADMA Biologics [NASDAQ:ADMA]  fell more than 45% on [...]

Top
SSL